US20020114768A1 - Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth - Google Patents

Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth Download PDF

Info

Publication number
US20020114768A1
US20020114768A1 US10/004,828 US482801A US2002114768A1 US 20020114768 A1 US20020114768 A1 US 20020114768A1 US 482801 A US482801 A US 482801A US 2002114768 A1 US2002114768 A1 US 2002114768A1
Authority
US
United States
Prior art keywords
bioactive glass
individual
less
microorganisms
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/004,828
Inventor
Patricia Stoor
Eva Soderling
Antti Yli-Urpo
Jukka Salonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/004,828 priority Critical patent/US20020114768A1/en
Publication of US20020114768A1 publication Critical patent/US20020114768A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C12/00—Powdered glass; Bead compositions
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C3/00—Glass compositions
    • C03C3/04—Glass compositions containing silica
    • C03C3/076—Glass compositions containing silica with 40% to 90% silica, by weight
    • C03C3/097—Glass compositions containing silica with 40% to 90% silica, by weight containing phosphorus, niobium or tantalum
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C4/00—Compositions for glass with special properties
    • C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C2204/00—Glasses, glazes or enamels with special properties
    • C03C2204/02—Antibacterial glass, glaze or enamel

Definitions

  • This invention relates to a method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention of dental caries and gingivitis, and for prevention or treatment of periapical infections, and whithening and/or mechanical cleaning of an individual's teeth.
  • Bioactive glasses have been tested as substitutes for reconstruction of defects of the facial bones (1), rehabilitation of the dentoalveolar complex (2), regeneration of periodontal pockets (3), and recently also for treatment of hypersensitive teeth (4).
  • the surface reactive bioactive glass contains SiO 2 , Na 2 O, CaO and P 2 O 5 .
  • the chemical bond with bone in vivo is reported to result from the leaching of Na + -ions and the congruent dissolution of calcium, phosphate and silica from the glass in an aqueous environment, giving rise to an Si-rich layer on the material.
  • the Si-rich layer acts as a templet for a calcium phosphate precipitation, which then binds to the bone (5).
  • Bioactive glass has been successfully used for reconstructions of closed bone defects, which are not exposed to the external environment after the clinical procedure (1).
  • conditions for which bioactive glasses are used as therapeutic materials include clinical conditions such as infected frontal sinuses (6), periodontal pockets (3) and hypersensitive teeth as a complication of periodontal treatment or tooth wear that has resulted in the exposure of dentin and dentinal tubules (4).
  • clinical conditions such as infected frontal sinuses (6), periodontal pockets (3) and hypersensitive teeth as a complication of periodontal treatment or tooth wear that has resulted in the exposure of dentin and dentinal tubules (4).
  • the demonstration of any antibacterial activity of the biactive glass would add to the therapeutic value of the material in the clinical conditions described. Earlier studies have shown that P.
  • gingivalis is agglutinated in the presence of granules (315-500 ⁇ m) of the bioactive glass S53P4 in an aqueous environment due to Ca +2 -ions released from the granules (19, 7).
  • the minimum Ca 2+ -concentration needed to induce agglutination of P. gingivalis was found to be 0.04 g/l (7). In these studies, however, no reduction of the viability of the bacteria was noticed.
  • an aqueous preparation comprising bioactive glass may have potential to be used as a paste for the treatment of hypersensitive teeth with recessed gingival margins and exposed dentine. Positive effects of such a treatment have been obtained already after 10 to 60 min, which makes this particular material interesting even from a clinical point of view (4).
  • the object of the present invention is to provide an easy, quick and safe method to reduce the viability of detrimental oral microorganisms in an individual.
  • a particular object is to achieve a method which is not based on use of antibiotic drugs associated with the risk of causing microbe restistence.
  • a particular object is to provide a method to reduce the viability of cariogenic bacteria and periodontal bacteria.
  • Another particular object is to provide a method to effectively reduce the viability of the detrimental oral microorganisms while the viability of non-pathogenic oral micro-organisms is reduced to a less degree.
  • a further object of this invention is to provide methods for prevention of dental caries and/or gingivitis, and for whitening of an individual's teeth, wherein said methods are due to the reduction of the viability and thus the decrease of the number of the detrimental oral micro-organisms.
  • Still one object is to achieve mechanical cleaning and whitening of an individual's teeth, wherein the whitening is a result of said mechanical cleaning.
  • the invention concerns a method for reducing the viability of detrimental oral microorganisms in an individual, said method comprising subjecting the individual's oral cavity to a bioactive glass, the average particle size of which is less than 100 ⁇ m.
  • the invention concerns a method for the prevention of dental caries and/or gingivitis in an individual, said caries being caused by a cariogenic bacteria, or for prevention or treatment of periapical infections, said method comprising subjecting the individual's oral cavity and/or root canals to a bioactive glass, the average particle size of which is less than 100 ⁇ m.
  • this invention concerns a method for the whitening of an individual's teeth, said method comprising subjecting the individual's oral cavity to a bioactive glass, the average particle size of which is less than 100 ⁇ m.
  • reducing the viability of detrimental oral micro-organisms shall be understood to include reduction to a certain decreased level as well as reduction to zero, i.e. complete elimination of viable microorganisms.
  • average particle size means that 50% of the number of particles have a size less than or equal to the value mentioned (e.g. 100 ⁇ m) and that 50% of the number of particles have a size greater than or equal to said value.
  • the average particle size is below 50 ⁇ m, most preferably about 20 ⁇ m or less.
  • the size of the individual particles may vary in a range extending from a value below 1 ⁇ m up to about 500 ⁇ m.
  • the “oral cavity” to be treated according to this invention means particularly the individual's teeth and periodontal regions in the mouth. Especially the individuals teeth down to the gingival margin and/or the periodontal pockets of the individual's mouth shall be treated, as well as root canals in endodontic treatment.
  • the bioactive glass is preferably administered as a composition comprising particles of the bioactive glass admixed into water or an aqueous solution. Especially preferable is a paste comprising about 40 to 80 weight-% of bioactive glass.
  • the composition can optionally also include other ingredients.
  • the composition is a tooth paste for regular use, including the bioactive glass.
  • bioactive glasses are the glass S53P4, which has the composition SiO 2 53%; CaO 20%; P 2 O 5 4% and Na 2 O 23%, and the glass 13-93, which has the composition SiO 2 53%; CaO 20%; P 2 O 5 4%, Na 2 O 6%, K 2 O 12% and MgO 5%.
  • the method according to the invention is particularly effective to reduce the viability of cariogenic bacteria, especially Actinomyces naeslundii and/or Streptococcus mutans .
  • periodontal bacteria i.e. bacteria causing gingivitis.
  • Typical periodontal bacteria are Actinobacillus actinomycetemcomitans and/or Porphyromonas gingivalis .
  • the reduction of the viability of non-pathogenic oral bacteria such as Streptococcus sanguis is lower than that for the detrimental oral microorganism. This is a very favourable feature, because essential reduction of the non-pathogenic oral bacteria is not wanted.
  • the duration of the treatment depends i.a. on the particular bioactive glass composition used, the average particle size, the bacteria in question, etc. As will be seen from the experimental data, a period of about 10 minutes may be enough to effectively eliminate viable cariogenic bacteria (bioactive glass S53P4, average particle size 20 ⁇ m), while a longer treatment is necessary for periodontal bacteria.
  • Oral bacteria are known to cause discolouring of teeth, as also coffee, tea, tobacco etc.
  • Bioactive glass is therefore, as an effective antibacterial agent and as a mechanically cleaning agent, useful for cleaning and whitening of the teeth.
  • Actinomyces naeslundii which is associated with root caries
  • Streptococcus mutans which is considered to play a major role in caries
  • Streptococcus sanguis as a representative of the benign oral microbiota (14).
  • the bioactive glass powder S53P4 used in this study was produced by Abmin Technologies Ltd, Turku, Finland.
  • the composition of the bioactive glass S53P4 given by weight is: SiO 2 53%, Na 2 O 23%, CaO 20% and P 2 O 5 4%.
  • the bioactive glass was prepared from reagent grade Na 2 CO 3 , CaHPO 4 ⁇ 2H 2 O, CaCO 3 (Merck, Darmstadt, Germany) and Belgium sand. The glass batches were melted for 3 h at 1360° C. After melting, the glass was cast into a plate, which was cooled from 520° C. to 220° C. at 1° C./min in an annealing oven. The oven was turned off and air-cooled to room temperature. The plate was crushed and dry ground in an agate mill. Powder, of particle size ⁇ 45 ⁇ m, (average particle size 20 ⁇ m), was sieved out of the batch (8).
  • the powder was combined with a microbial suspension using a ratio of glass powder and liquid (50 mg and 30 ⁇ l, respectively), simulating the composition used for treatment of hypersensitive teeth (4).
  • the microorganisms used were Actinobacillus actinomycetemcomitans (ATCC 29523), Porphyromonas gingivalis (ATCC 33277), Actinomyces naeslundii (clinical isolate), Streptococcus mutans (NCTC 10449) and Streptococcus sanguis (NCTC 10904).
  • RDF Reduced Transport Fluid
  • the suspensions were adjusted with saline or RTF to an optical density of approximately 1.0 [A 700 ; corresponding to 10 5 -10 7 colony forming units, (CFU)/ml].
  • P. gingivalis was precultivated anaerobically (80% N 2 , 10% CO 2 , 10% H 2 ) at 37° C. on Brucella agar plates (Difco Laboratories, Detroit, USA).
  • the cells were harvested after 6 days' growth, washed once in Brewer Thioglycollate medium (500 g/l Beef Infusion, 5 g/l NaCl, 2 g/l K 2 HPO 4 , 10 g/l Proteose Peptone, 5 g/l Bacto Dextrose, 0.5 g/l Na-Thioglycollate, 0.5 g/l Bacto Agar, 0.002 g/l Bacto Methylene Blue) and finally adjusted with Brewer Thioglycollate medium to an optical density of approximately 1.0 (A 700 ; corresponding to 10 4 -10 5 CFU/ml).
  • naeslundii was precultivated in Brewer Thioglycollate medium (Difco) at 37° C. for 3 days, washed once in RTF and adjusted with RTF to a density of approximately 1.0 (A 700 ; corresponding to 10 5 -10 6 CFU/ml).
  • bioactive glass powder 50 mg
  • 30 ⁇ l of the microbial suspension were first vortexed for thorough mixing for 10 min at room temperature in Eppendorf tubes (Sarstedt, Germany), followed by incubation without agitation for 50 min at 37° C.
  • the controls contained 1) no added bioactive glass powder or 2) 50 mg inert SiO 2 powder (particle size ⁇ 45 ⁇ m).
  • actinomycetemcomitans and A. naeslundii were cultivated on blood agar anaerobically at 37° C. for 3 days and approximately 18 h, respectively.
  • P. gingivalis was cultivated anaerobically at 37° C. for 6 days on Brucella agar plates.
  • S. mutans and S. sanguis were cultivated on Mitis salivarius agar for approximately 18 h at 37° C. aerobically in an atmosphere consisting of 74% N 2 , 19% O 2 and 7% CO 2 . The experiment was performed with 2-3 parallels and repeated once.
  • Table 2 Measurements of the release of four elements from the bioactive glass S53P4 in powdered form, showing almost instant release of calcium, phosphorous and sodium. The amount of released silicon tripled during the time period, 10-60 min. The values shown are means ⁇ standard deviations (s) in mg/l. 10 min 60 min Element Mean s Mean s Ca 2990 ⁇ 210 3520 ⁇ 190 P 170 ⁇ 30 160 ⁇ 000 Si 1440 ⁇ 120 4740 ⁇ 50 Na 33790 ⁇ 540 34980 ⁇ 220
  • A. actinomycetemcomitans totally lost its viability in contact with the bioactive glass powder within 60 min.
  • a major decrease in the number of viable microbes was already seen within 10 min, as the number of viable microbes decreased from 9 ⁇ 10 5 to 9 ⁇ 10 2 .
  • P. gingivalis lost its viability in contact with the glass powder within 60 min. After 10 min, a decrease from 9 ⁇ 10 4 to 1 ⁇ 10 3 in the number of viable cells was seen.
  • S. mutans lost its viability almost totally, from 6 ⁇ 10 6 to 0.8 ⁇ 10 1 , after 10 min incubation with the bioactive glass powder. A total loss of viability of A. naeslundii was also seen already after 10 min. S.
  • sanguis showed a significant loss of viability, at 10 min, from 7 ⁇ 10 6 to 1 ⁇ 10 4 and at 60 min, further down to 1 ⁇ 10 3 . (FIG. 1). However, S. sanguis was the only microbe that had any viable cells left after 60 min.
  • bioactive glass paste showed a broad antibacterial effect on the microorganisms tested.
  • the effect found may be due to several influences including high pH, osmotic effects and the Ca 2+ -concentration (7).
  • the bioactive glass S53P4 reacts in a surface reactive manner in an aqueous environment, the release of ions and consequently the rise of the pH increases with an increasing surface area of the glass.
  • the surface area of the glass In the form of a powder ( ⁇ 45 ⁇ m) the surface area of the glass is large per weight unit, and thus the release of ions is high.
  • the surface area/volume (SA/V) ratio was very high, approximately 1920 cm ⁇ 1 .
  • Earlier experiments with bioactive glass S53P4 granules (297-500 ⁇ m) where the SA/V ratio was 0.4 cm ⁇ 1 showed almost a linear increase in release of ions during the first 7 hours (16).
  • gingivalis is reported to be a more efficient permeability barrier than the cell wall of the gram-positive bacteria ( A. naeslundii, S. mutans, S. sanguis ) (18), the osmotic effects due to the bioactive glass paste could partly explain the relative resistance of the gram-negative microorganisms and the more rapid loss of viability of A. naeslundii and S. mutans . Because S. sanguis , despite the lack of an effective permeability barrier, was the only microbe that managed to maintain some viability also other mechanisms must be involved.
  • the bioactive glass paste appears to possess a broad antimicrobial effect on microorganisms of both supra- and subgingival plaque. Consequently, the bioactive glass paste may have beneficial effects on oral health both from a cariological and a periodontal point of view, in addition to its more direct therapeutic effect on root surface hypersensivity.
  • the clinical benefits of the bioactive glass powder when used as a paste or as a component in toothcare products come from a combination of good influences rather than from any single property, such as its ability to reduce bacterial growth. These influences include mechanical cleaning and remineralisation of both dentine and enamel.
  • Nolte W A Physiology and growth of microorganisms. In: Nolte W A, editor. Oral Microbiology with basic microbiology and immunology. 3rd ed. St. Louis: The C.V. Mosby Company; 1977. p. 25-38.
  • Greenwood D Morphology and nature of microorganisms. In: Greenwood D, Slack R, Koherer J, editors. Medical Microbiology. 14th ed. Churchill Livingstone: Longman Group UK Limited; 1992. p.11-30.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ceramic Engineering (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)

Abstract

The invention relates to a method for reducing the viability of detrimental oral microorganisms in an individual, said method comprising subjecting the individual's oral cavity to a bioactive glass, the average particle size of which is less than 100 μm.
Furthermore, this invention concerns a method for the prevention of dental caries and/or gingivitis in an individual, said caries being caused by a cariogenic bacteria; or for prevention or treatment of periapical infections.
Further the invention relates to a method for the whitening and/or mechanical cleaning of an individual's teeth.

Description

    FIELD OF THE INVENTION
  • This invention relates to a method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention of dental caries and gingivitis, and for prevention or treatment of periapical infections, and whithening and/or mechanical cleaning of an individual's teeth. [0001]
  • BACKGROUND OF THE INVENTION
  • The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference. [0002]
  • Bioactive glasses have been tested as substitutes for reconstruction of defects of the facial bones (1), rehabilitation of the dentoalveolar complex (2), regeneration of periodontal pockets (3), and recently also for treatment of hypersensitive teeth (4). The surface reactive bioactive glass contains SiO[0003] 2, Na2O, CaO and P2O5. The chemical bond with bone in vivo is reported to result from the leaching of Na+-ions and the congruent dissolution of calcium, phosphate and silica from the glass in an aqueous environment, giving rise to an Si-rich layer on the material. The Si-rich layer acts as a templet for a calcium phosphate precipitation, which then binds to the bone (5). Bioactive glass has been successfully used for reconstructions of closed bone defects, which are not exposed to the external environment after the clinical procedure (1). However, there are a number of conditions for which bioactive glasses are used as therapeutic materials but that, at the same time, are imminently prone to microbial infections. These include clinical conditions such as infected frontal sinuses (6), periodontal pockets (3) and hypersensitive teeth as a complication of periodontal treatment or tooth wear that has resulted in the exposure of dentin and dentinal tubules (4). Obviously, the demonstration of any antibacterial activity of the biactive glass would add to the therapeutic value of the material in the clinical conditions described. Earlier studies have shown that P. gingivalis is agglutinated in the presence of granules (315-500 μm) of the bioactive glass S53P4 in an aqueous environment due to Ca+2-ions released from the granules (19, 7). The minimum Ca2+-concentration needed to induce agglutination of P. gingivalis was found to be 0.04 g/l (7). In these studies, however, no reduction of the viability of the bacteria was noticed.
  • Earlier studies have shown that the bioactive glass can act as a vehicle for Ca[0004] 2+, PO4 3−, Na+ and Si4+, which then mineralise type I collagen and enhance mineral formation in the dentinal tubules. Therefore, an aqueous preparation comprising bioactive glass may have potential to be used as a paste for the treatment of hypersensitive teeth with recessed gingival margins and exposed dentine. Positive effects of such a treatment have been obtained already after 10 to 60 min, which makes this particular material interesting even from a clinical point of view (4).
  • OBJECT AND SUMMARY OF THE INVENTION
  • The object of the present invention is to provide an easy, quick and safe method to reduce the viability of detrimental oral microorganisms in an individual. A particular object is to achieve a method which is not based on use of antibiotic drugs associated with the risk of causing microbe restistence. [0005]
  • A particular object is to provide a method to reduce the viability of cariogenic bacteria and periodontal bacteria. [0006]
  • Another particular object is to provide a method to effectively reduce the viability of the detrimental oral microorganisms while the viability of non-pathogenic oral micro-organisms is reduced to a less degree. [0007]
  • A further object of this invention is to provide methods for prevention of dental caries and/or gingivitis, and for whitening of an individual's teeth, wherein said methods are due to the reduction of the viability and thus the decrease of the number of the detrimental oral micro-organisms. [0008]
  • Still one object is to achieve mechanical cleaning and whitening of an individual's teeth, wherein the whitening is a result of said mechanical cleaning. [0009]
  • Thus, according to one aspect, the invention concerns a method for reducing the viability of detrimental oral microorganisms in an individual, said method comprising subjecting the individual's oral cavity to a bioactive glass, the average particle size of which is less than 100 μm. [0010]
  • According to another aspect, the invention concerns a method for the prevention of dental caries and/or gingivitis in an individual, said caries being caused by a cariogenic bacteria, or for prevention or treatment of periapical infections, said method comprising subjecting the individual's oral cavity and/or root canals to a bioactive glass, the average particle size of which is less than 100 μm. [0011]
  • According to a further aspect, this invention concerns a method for the whitening of an individual's teeth, said method comprising subjecting the individual's oral cavity to a bioactive glass, the average particle size of which is less than 100 μm.[0012]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1A to [0013] 1E show the effect of 1) the powdered bioactive glass S53P4 (continuous lines) and 2) control containing no bioactive glass (dashed lines) on the number of viable microbes in suspension. Values shown are means; bars indicate range; n=3. CFU=colony-forming units.
  • FIGS. 2A to [0014] 2E show the effect of 1) SiO2 powder (continuous lines) and 2) control containing no SiO2 powder (dashed lines) on the number of viable counts microbes in suspension. Values shown are means; bars indicate range; n=2 to 3. CFU=colony-forming units.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The term “reducing the viability of detrimental oral micro-organisms” shall be understood to include reduction to a certain decreased level as well as reduction to zero, i.e. complete elimination of viable microorganisms. [0015]
  • The term “average particle size” means that 50% of the number of particles have a size less than or equal to the value mentioned (e.g. 100 μm) and that 50% of the number of particles have a size greater than or equal to said value. [0016]
  • According to a preferred embodiment, the average particle size is below 50 μm, most preferably about 20 μm or less. The size of the individual particles may vary in a range extending from a value below 1 μm up to about 500 μm. [0017]
  • The “oral cavity” to be treated according to this invention means particularly the individual's teeth and periodontal regions in the mouth. Especially the individuals teeth down to the gingival margin and/or the periodontal pockets of the individual's mouth shall be treated, as well as root canals in endodontic treatment. [0018]
  • The bioactive glass is preferably administered as a composition comprising particles of the bioactive glass admixed into water or an aqueous solution. Especially preferable is a paste comprising about 40 to 80 weight-% of bioactive glass. The composition can optionally also include other ingredients. According to an especially preferable embodiment, the composition is a tooth paste for regular use, including the bioactive glass. [0019]
  • Some typical and preferable bioactive glass compositions are presented in Table 1. [0020]
    TABLE 1
    Composition (weight-%) of some bioactive glass types 1-17
    Glass Type Na2O CaO P2O5 B2O3 Al2O3 SiO2
     1 S63.5P6 15.00 14.00 6.00 0.50 1.00 63.50
     2 S57.5P5 16.00 18.00 5.00 3.00 0.50 57.50
     3 S65.SP1 17.00 13.00 1.00 1.00 2.50 65.50
     4 S52P3 18.00 24.00 3.00 0.00 3.00 52.00
     5 S56P6 19.00 16.00 6.00 1.50 1.50 56.00
     6 S51P7 20.00 17.00 7.00 3.00 2.00 51.00
     7 S51P2 21.00 21.00 2.00 2.00 3.00 51.00
     8 S64P0 22.00 10.00 0.00 2.50 1.50 64.00
     9 S53P4 23.00 20.00 4.00 0.00 0.00 53.00
    10 S45P7 24.00 22.00 7.00 2.00 0.00 45.00
    11 S52P8 25.00 12.00 8.00 0.50 2.50 52.00
    12 S46P0 26.00 25.00 0.00 2.00 1.00 46.00
    13 S38P8 27.00 23.00 8.00 1.00 3.00 38.00
    14 S48P2 28.00 19.00 2.00 1.50 1.50 48.00
    15 S55.5P4 29.00 11.00 4.00 0.00 0.50 55.50
    16 S45.5P5 30.00 15.00 5.00 2.50 2.00 45.50
    17x) 13-93 6.00 20.00 4.00 0.00 0.00 53.00
  • Particularly preferable bioactive glasses are the glass S53P4, which has the composition SiO[0021] 2 53%; CaO 20%; P2O5 4% and Na2O 23%, and the glass 13-93, which has the composition SiO2 53%; CaO 20%; P2O5 4%, Na2O 6%, K2O 12% and MgO 5%.
  • The method according to the invention is particularly effective to reduce the viability of cariogenic bacteria, especially [0022] Actinomyces naeslundii and/or Streptococcus mutans. Also periodontal bacteria (i.e. bacteria causing gingivitis). Typical periodontal bacteria are Actinobacillus actinomycetemcomitans and/or Porphyromonas gingivalis. However, the reduction of the viability of non-pathogenic oral bacteria such as Streptococcus sanguis is lower than that for the detrimental oral microorganism. This is a very favourable feature, because essential reduction of the non-pathogenic oral bacteria is not wanted.
  • The duration of the treatment depends i.a. on the particular bioactive glass composition used, the average particle size, the bacteria in question, etc. As will be seen from the experimental data, a period of about 10 minutes may be enough to effectively eliminate viable cariogenic bacteria (bioactive glass S53P4, average particle size 20 μm), while a longer treatment is necessary for periodontal bacteria. [0023]
  • Oral bacteria are known to cause discolouring of teeth, as also coffee, tea, tobacco etc. Bioactive glass is therefore, as an effective antibacterial agent and as a mechanically cleaning agent, useful for cleaning and whitening of the teeth. [0024]
  • The invention is described in more detail in the Experimental Section. [0025]
  • Experimental Section [0026]
  • The purpose of this study was to examine the antibacterial effects of a paste made of the bioactive glass S53P4 (8) on oral microorganisms representing periodontal pathogens, caries-associated microorganisms and benign oral microflora. Two major pathogens were used: [0027] Actinobacillus actinomycetemcomitans, which has been suggested to play a role in juvenile periodontitis (9, 10), and Porphyromonas gingivalis, which has been associated with destructive periodontal lesions in adults (11, 12, 13). Also were studied Actinomyces naeslundii, which is associated with root caries; Streptococcus mutans, which is considered to play a major role in caries; and Streptococcus sanguis as a representative of the benign oral microbiota (14).
  • Materials and Methods [0028]
  • Materials [0029]
  • The bioactive glass powder S53P4 used in this study was produced by Abmin Technologies Ltd, Turku, Finland. The composition of the bioactive glass S53P4 given by weight is: SiO[0030] 2 53%, Na2O 23%, CaO 20% and P2O5 4%. The bioactive glass was prepared from reagent grade Na2CO3, CaHPO4×2H2O, CaCO3 (Merck, Darmstadt, Germany) and Belgium sand. The glass batches were melted for 3 h at 1360° C. After melting, the glass was cast into a plate, which was cooled from 520° C. to 220° C. at 1° C./min in an annealing oven. The oven was turned off and air-cooled to room temperature. The plate was crushed and dry ground in an agate mill. Powder, of particle size <45 μm, (average particle size 20 μm), was sieved out of the batch (8).
  • The powder was combined with a microbial suspension using a ratio of glass powder and liquid (50 mg and 30 μl, respectively), simulating the composition used for treatment of hypersensitive teeth (4). [0031]
  • As controls we used 1) no added glass powder and 2) an inert SiO[0032] 2 powder, containing 100% SiO2, of particle size <45 μm (Biomaterials project, Institute of Dentistry, University of Turku, Finland).
  • Microorganisms [0033]
  • The microorganisms used were [0034] Actinobacillus actinomycetemcomitans (ATCC 29523), Porphyromonas gingivalis (ATCC 33277), Actinomyces naeslundii (clinical isolate), Streptococcus mutans (NCTC 10449) and Streptococcus sanguis (NCTC 10904).
  • Preparation of the Microbial Suspensions [0035]
  • Precultivation of [0036] A. actinomycetemcomitans, S. mutans and S. sanguis was performed at 37° C. in BHI (Brain Heart Infusion, Unipath Ltd, Hampshire, England). After approximately 18 h of growth, the cells were washed once in saline (S. mutans and S. sanguis) or in Reduced Transport Fluid (RTF: 0.6 g/l K2HPO4×3H2O, 0.23 g/l NaCl, 0.23 g/l (NH4)2SO4, 0.11 g/l KH2PO4, 0.1 g/l MgSO4×7H2O, 0.37 g/l disodium ethylenedinitrilo tetraacetate; C10H14N2Na2O8×2H2O, 0.4 g/l Na2CO3, 0.2 g/l dithiothreitol; C4H10O2S2) (15) (A. actinomycetemcomitans). The suspensions were adjusted with saline or RTF to an optical density of approximately 1.0 [A700; corresponding to 105-107 colony forming units, (CFU)/ml]. P. gingivalis was precultivated anaerobically (80% N2, 10% CO2, 10% H2) at 37° C. on Brucella agar plates (Difco Laboratories, Detroit, USA). The cells were harvested after 6 days' growth, washed once in Brewer Thioglycollate medium (500 g/l Beef Infusion, 5 g/l NaCl, 2 g/l K2HPO4, 10 g/l Proteose Peptone, 5 g/l Bacto Dextrose, 0.5 g/l Na-Thioglycollate, 0.5 g/l Bacto Agar, 0.002 g/l Bacto Methylene Blue) and finally adjusted with Brewer Thioglycollate medium to an optical density of approximately 1.0 (A700; corresponding to 104-105 CFU/ml). A. naeslundii was precultivated in Brewer Thioglycollate medium (Difco) at 37° C. for 3 days, washed once in RTF and adjusted with RTF to a density of approximately 1.0 (A700; corresponding to 105-106 CFU/ml).
  • Incubation Experiments [0037]
  • The bioactive glass powder (50 mg) and 30 μl of the microbial suspension were first vortexed for thorough mixing for 10 min at room temperature in Eppendorf tubes (Sarstedt, Germany), followed by incubation without agitation for 50 min at 37° C. The controls contained 1) no added bioactive glass powder or 2) 50 mg inert SiO[0038] 2 powder (particle size <45 μm).
  • For assessment of viability as CFU, the incubation was stopped by adding 470 μl RTF ([0039] A. Actinomycetemcomitans, P. gingivalis, A. naeslundii) or saline (S. mutans, S. sanguis), followed by vortexing and gentle sonication for 2 s to detach the microorganisms from the bioactive glass powder and from the inert SiO2 powder. The assessment of viability as CFU of the microbial suspensions was performed on solid growth media by cultivating 10 μl samples from the suspensions diluted in saline (101-107). The undiluted suspension was also cultivated by using 20 μl samples. A. actinomycetemcomitans and A. naeslundii were cultivated on blood agar anaerobically at 37° C. for 3 days and approximately 18 h, respectively. P. gingivalis was cultivated anaerobically at 37° C. for 6 days on Brucella agar plates. S. mutans and S. sanguis were cultivated on Mitis salivarius agar for approximately 18 h at 37° C. aerobically in an atmosphere consisting of 74% N2, 19% O2 and 7% CO2. The experiment was performed with 2-3 parallels and repeated once.
  • Ion Release from the Bioactive Glass Paste and Related pH Changes [0040]
  • The release of ions from the bioactive glass powder (50 mg) during the 60 min contact with saline (30 μl) was analyzed with a Direct Current Plasma Atomic Emission Spectroscopy DCP-AES at the Department of Chemistry at Åbo Akademi University, Turku, Finland. The determinations were performed in triplicate. After the vortexing (10 min) and incubation (50 min) the samples were suspended in 5 ml laboratory grade H[0041] 2O (Milli-QUF PLUS, Millipore, Molsheim, France), rapidly mixed and immediately filtrated with a Millex-GS 0.22 mm filter (Millipore).
  • The time-dependent changes in the pH values of saline and Brewer Thioglycollate medium were monitored after 10-min and 60-min incubation with the bioactive glass powder. The measurements were performed with a combination electrode pHC4406 (Radiometer, Copenhagen, Denmark). [0042]
  • Results [0043]
  • The time-dependent release of calcium, phosphorous, silica and sodium from the bioactive glass paste is given in Table 2. For calcium, phosphorous and sodium, the amount of released ions did not increase during the prolonged incubation, but for silica the amount tripled during the 10-60-min incubation. The increased osmotic pressure was created mostly by an almost immediate release of high amounts of sodium, which corresponds to a concentration of 3.38% at 10 min and 3.50% at 60 min. [0044]
  • Table 2. Measurements of the release of four elements from the bioactive glass S53P4 in powdered form, showing almost instant release of calcium, phosphorous and sodium. The amount of released silicon tripled during the time period, 10-60 min. The values shown are means±standard deviations (s) in mg/l. [0045]
    10 min 60 min
    Element Mean s Mean s
    Ca 2990 ± 210 3520 ± 190
    P 170 ± 30 160 ± 000
    Si 1440 ± 120 4740 ± 50
    Na 33790 ± 540 34980 ± 220
  • During the incubation with bioactive glass powder, the mean (±standard deviation) of the pH of both the saline and the Brewer Thioglycollate medium increased in 10 min from 6.9 (±0.3) to 10.8 (±0.1). No further increase of the pH was seen. [0046]
  • [0047] A. actinomycetemcomitans totally lost its viability in contact with the bioactive glass powder within 60 min. A major decrease in the number of viable microbes was already seen within 10 min, as the number of viable microbes decreased from 9×105 to 9×102. Also P. gingivalis lost its viability in contact with the glass powder within 60 min. After 10 min, a decrease from 9×104 to 1×103 in the number of viable cells was seen. S. mutans lost its viability almost totally, from 6×106 to 0.8×101, after 10 min incubation with the bioactive glass powder. A total loss of viability of A. naeslundii was also seen already after 10 min. S. sanguis showed a significant loss of viability, at 10 min, from 7×106 to 1×104 and at 60 min, further down to 1×103. (FIG. 1). However, S. sanguis was the only microbe that had any viable cells left after 60 min.
  • The incubations with the reference material, the inert SiO[0048] 2, powder, showed results similar to those of the controls with no glass powder (FIG. 2).
  • Discussion [0049]
  • In this study the bioactive glass paste showed a broad antibacterial effect on the microorganisms tested. The effect found may be due to several influences including high pH, osmotic effects and the Ca[0050] 2+-concentration (7).
  • Since the bioactive glass S53P4 reacts in a surface reactive manner in an aqueous environment, the release of ions and consequently the rise of the pH increases with an increasing surface area of the glass. In the form of a powder (<45 μm) the surface area of the glass is large per weight unit, and thus the release of ions is high. In our experiments the surface area/volume (SA/V) ratio was very high, approximately 1920 cm[0051] −1. Earlier experiments with bioactive glass S53P4 granules (297-500 μm) where the SA/V ratio was 0.4 cm−1 showed almost a linear increase in release of ions during the first 7 hours (16). Owing to the high SA/V ratio in the present experiment the release of ions was up to ×300 times greater during the 60 min incubation than in the earlier experiments with granules (60 min: Ca 24 mg/l, P not detected, Si 15 mg/l, Na 12 mg/l) (16). Thus, the release of ions was faster from the bioactive powder than from the granules. Also the pH change observed with the <45-μm glass powder within 60 min (pH 7->11) was higher than that reported with granules earlier (pH 7->9) (8).
  • Most heterotrophic bacteria grow well in media with an osmotic pressure created by 0.75% salt. Concentrations higher than 1% become inhibitory for most bacteria. However, many streptococci of the oral cavity can grow well on a 5% sucrose medium, while the growth of most other oral bacteria is inhibited under such conditions (17). As judged by the concentrations of the separate ions released from the glass powder, the total osmotic pressure was, already after 10 min, created by a concentration higher than 3% and, after 60 min, by a concentration above 4% (see Table 2). Since the outer membrane of gram-negative bacteria ([0052] A. actinomycetemcomitans, P. gingivalis) is reported to be a more efficient permeability barrier than the cell wall of the gram-positive bacteria (A. naeslundii, S. mutans, S. sanguis) (18), the osmotic effects due to the bioactive glass paste could partly explain the relative resistance of the gram-negative microorganisms and the more rapid loss of viability of A. naeslundii and S. mutans. Because S. sanguis, despite the lack of an effective permeability barrier, was the only microbe that managed to maintain some viability also other mechanisms must be involved.
  • The Ca[0053] +2-ion concentration measured in association with the paste of bioactive glass powder used in this study was much higher (3.0-3.5 g/l) than that shown (0.04 g/l ) in the earlier study (7) using granules (315-500 μm) of the same bioactive glass.
  • In addition to the immediate antibacterial effect due to the instant release of ions from the bioactive glass, possible residues of bioactive glass cause long term effects over days and even months, due to the continuing leaching of ions from the bioactive glass. [0054]
  • In conclusion, the bioactive glass paste appears to possess a broad antimicrobial effect on microorganisms of both supra- and subgingival plaque. Consequently, the bioactive glass paste may have beneficial effects on oral health both from a cariological and a periodontal point of view, in addition to its more direct therapeutic effect on root surface hypersensivity. Apparently, the clinical benefits of the bioactive glass powder when used as a paste or as a component in toothcare products come from a combination of good influences rather than from any single property, such as its ability to reduce bacterial growth. These influences include mechanical cleaning and remineralisation of both dentine and enamel. [0055]
  • It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive. [0056]
  • References [0057]
  • 1. Suominen E A, Kinnunen J. Bioactive glass granules and plates in the reconstruction of defects of the facial bones. Scand J Plast Reconstr Surg Hand Surg 1996;30:281-9. [0058]
  • 2. Wilsin J, Clark A E, Douek E, Krieger J, Smith W K, Zamet J S. Clinical applications of bioglass implants. In: Andersson Ö H, Happonen R-P, editors. Bioceramics Vol 7. Cambridge: Butterworth-Heinmann Ltd; 1994. p. 415-22. [0059]
  • 3. Larmas E, Sewón L, Luostarinen T, Kangasniemi I, Yli-Urpo A. Bioactive glass in periodontal defects. Initial clinical findings of soft tissue and osseus repair. In: Wilson J, Hench L L, Greenspan D, editors. [0060] Bioceramics Vol 8. Oxford: Elsevier Science Ltd; 1995. p. 279-84.
  • 4. Salonen J, Tuominen U, Andersson Ö H. Mineralization of dentine by making use of bioactive glass S53P4. In: Andersson Ö H, Salonen J, Yli-Urpo A, editors. Biomaterials Today and Tomorrow, Proceedings of the Finnish Dental Society. Turku: Turku Centre for Biomaterials; 1996. p. 25-6. [0061]
  • 5. Hench L L, Paschall H A. Direct chemical bond of bioactive glass-ceramic materials to bone and muscle. J Biomed Mater Res 1973;7:25-42. [0062]
  • 6. Aitasalo K, Suonpää J, Peltola M, Yli-Urpo A. Behaviour of bioactive glass (S53P4) in human frontal sinus obliteration. Sedel L, Rey C, editors. [0063] Bioceramics Vol 10. Oxford: Elsevier Science Ltd; 1997. p. 429-32.
  • 7. Stoor P, Kirstilä V, Söderling E, Kangasniemi I, Herbst K, Yli-Urpo A. Interactions between bioactive glass and periodontal pathogens. Microb Ecol Health Dis 1996;9:109-14. [0064]
  • 8. Andersson Ö. The bioactivity of a Silicate Glass. Thesis, Åbo Akademi University, Finland; 1990. [0065]
  • 9. Newman M G, Socransky S S, Savitt E D, Propas D A, Crawford A. Studies of the microbiology of periodontitis. J Periodont 1976;47:373-79. [0066]
  • 10. Slots J. The predominant cultivable organisms in juvenile periodontitis. Scand J Dent Res 1976;84:1-10. [0067]
  • 11. Slots J. The predominant cultivable microflora of advanced periodontitis. J Dent Res 1977;85:114-21. [0068]
  • 12. Spiegel C A, Hayduk E S, Minah G E, Kryoplan G N. Black pigmented bacteroides from clinically characterized periodontal sites. J Periodont Res 1979;14:376-82. [0069]
  • 13. Tanner A C R, Haffer C, Bratthall G T, Visconti R A, Socransky S S. A study of the bacteria associated with advancing periodontal disease in man. J Clin Periodont 1979;6:278-307. [0070]
  • 14. Burnett G W, Schuster G S. Oral microbiota and its disease. In: Burnett G W, Schuster G S, editors. Oral microbiology and infectious disease. Student edition. Baltimore: The Williams & Wilkins Company; 1978. p. 174-253. [0071]
  • 15. Syed S A, Loesche W J. Survival of human dental plaque flora in various transport media. Appl Microbiol 1972;24:638-44. [0072]
  • 16. Andersson Ö H, Rosenqvist J, Karlsson K H. Dissolution, leaching, and Al[0073] 2O3 enrichment at the surface of bioactive glasses studied by solution analysis. J Biomed Mater Res 1993;27:941-48.
  • 17. Nolte W A. Physiology and growth of microorganisms. In: Nolte W A, editor. Oral Microbiology with basic microbiology and immunology. 3rd ed. St. Louis: The C.V. Mosby Company; 1977. p. 25-38. [0074]
  • 18. Greenwood D. Morphology and nature of microorganisms. In: Greenwood D, Slack R, Peutherer J, editors. Medical Microbiology. 14th ed. Churchill Livingstone: Longman Group UK Limited; 1992. p.11-30. [0075]
  • 19. Yamashita Y, Kunimori A, Takehara T. Effect of Ca ions on cell surface electrostatics of Bacterioides gingivalis and other oral bacteria. Zentralblatt für Bacteriologie 1991;275:46-53. [0076]
  • 20. Cimasoni G. In: Myers H, editor. Crevicular Fluid Updated. 2nd ed. Basel: Krager; 1983. p. 70-1. [0077]
  • 21. Barbosa S V, Spangberg S W, Almedia D. Low surface tension calcium hydroxide solution is an effective antiseptic. Int Endod J 1994;27:6-10. [0078]
  • 22. Drake D R, Vargas K, Cardenzana A, Srikantha R. Enhanced bactericidical activity of Arm and Hammer Dental Care. Am J Dent 1995;8:308-12. [0079]
  • 23. Morrier J J, Rocca J P, Barsotti O. Antibacterial action of dental cements. Bull Group Int Rech Sci Stomatol Odontol 1995;38:87-93. [0080]

Claims (24)

1. A method for reducing the viability of detrimental oral microorganisms in an individual, said method comprising subjecting the individual's oral cavity to a bioactive glass, the average particle size of which is less than 100 μm.
2. The method according to claim 1, wherein the average particle size is less than 50 μm, preferably about 20 μm or less.
3. The method according to claim 1, wherein the bioactive glass is administered as a composition comprising particles of the bioactive glass admixed into water or an aqueous solution.
4. The method according to claim 3, wherein the composition is a paste comprising about 40 to 80 weight-% of bioactive glass.
5. The method according to claim 1, wherein the bioactive glass is selected from a bioactive glass having the composition SiO2 53%; CaO 20%; P2O5 4% and Na2O 23% by weight, or SiO2 53%; CaO 20%; P2O5 4%, Na2O 6%, K2O 12% and MgO 5% by weight.
6. The method according to claim 1, wherein the detrimental oral microorganisms are cariogenic bacteria.
7. The method according to claim 6, wherein the cariogenic bacteria are Actinomyces naeslundii and/or Streptococcus mutans.
8. The method according to claim 1, wherein the detrimental oral microorganisms are periodontal bacteria.
9. The method according to claim 8, wherein the periodontal bacteria are Actinobacillus actinomycetemcomitans and/or Porphyromonas gingivalis.
10. The method according to claim 1, wherein the treatment is carried out for about 10 minutes.
11. The method according to claim 1, wherein the viability of benign oral microorganisms is reduced less than the viability of the detrimental oral microorganisms.
12. The method according to claim 12, wherein the benign oral microorganism is Streptococcus sanguis.
13. A method for the prevention of dental caries and/or gingivitis in an individual, said caries being caused by a cariogenic bacteria, or for prevention or treatment of periapical infections, said method comprising subjecting the individual's oral cavity and/or root canals to a bioactive glass, the average particle size of which is less than 100 μm.
14. The method according to claim 13, wherein the average particle size is less than 50 μm, preferably about 20 μm or less.
15. The method according to claim 13, wherein the bioactive glass is administered as a composition comprising particles of the bioactive glass admixed into water or an aqueous solution.
16. The method according to claim 15, wherein the composition is a paste comprising about 40 to 80 weight-% of bioactive glass.
17. The method according to claim 13, wherein the bioactive glass is selected from a bioactive glass having the composition SiO2 53%; CaO 20%; P2O5 4% and Na2O 23% by weight, or SiO2 53%; CaO 20%; P2O5 4%, Na2O 6%, K2O 12% and MgO 5% by weight.
18. The method according to claim 17, wherein the cariogenic bacteria are Actinomyces naeslundii and/or Streptococcus mutans.
19. The method according to claim 13, wherein the treatment is carried out for about 10 minutes.
20. A method for the whitening and/or mechanical cleaning of an individual's teeth, said method comprising subjecting the individual's oral cavity to a bioactive glass, the average particle size of which is less than 100 μm.
21. The method according to claim 20, wherein the average particle size is less than 50 μm, preferably about 20 μm or less.
22. The method according to claim 20, wherein the bioactive glass is administered as a composition comprising particles of the bioactive glass admixed into water or an aqueous solution.
23. The method according to claim 22, wherein the composition is a paste comprising about 40 to 80 weight-% of bioactive glass.
24. The method according to claim 20, wherein the bioactive glass is selected from a bioactive glass having the composition SiO2 53%; CaO 20%; P2O5 4% and Na2O 23% by weight, or SiO2 53%; CaO 20%; P2O5 4%, Na2O 6%, K2O 12% and MgO 5% by weight.
US10/004,828 1999-03-02 2001-12-07 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth Abandoned US20020114768A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/004,828 US20020114768A1 (en) 1999-03-02 2001-12-07 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/260,081 US6190643B1 (en) 1999-03-02 1999-03-02 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth
US09/690,810 US6342207B1 (en) 1999-03-02 2000-10-18 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth
US10/004,828 US20020114768A1 (en) 1999-03-02 2001-12-07 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/690,810 Division US6342207B1 (en) 1999-03-02 2000-10-18 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth

Publications (1)

Publication Number Publication Date
US20020114768A1 true US20020114768A1 (en) 2002-08-22

Family

ID=22987692

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/260,081 Expired - Lifetime US6190643B1 (en) 1999-03-02 1999-03-02 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth
US09/690,810 Expired - Lifetime US6342207B1 (en) 1999-03-02 2000-10-18 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth
US10/004,828 Abandoned US20020114768A1 (en) 1999-03-02 2001-12-07 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/260,081 Expired - Lifetime US6190643B1 (en) 1999-03-02 1999-03-02 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth
US09/690,810 Expired - Lifetime US6342207B1 (en) 1999-03-02 2000-10-18 Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual's teeth

Country Status (2)

Country Link
US (3) US6190643B1 (en)
CA (1) CA2272963C (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040151745A1 (en) * 2001-03-27 2004-08-05 Jose Zimmer Tissue abrasives
DE102004026432A1 (en) * 2004-05-29 2005-12-22 Schott Ag Glass compositions as antimicrobial additive for dental materials and their use
US20060142413A1 (en) * 2003-02-25 2006-06-29 Jose Zimmer Antimicrobial active borosilicate glass
US20070258916A1 (en) * 2006-04-14 2007-11-08 Oregon Health & Science University Oral compositions for treating tooth hypersensitivity
US20070275021A1 (en) * 1999-12-07 2007-11-29 Schott Ag New cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
US20090317339A1 (en) * 2008-06-23 2009-12-24 Deepak Sharma Teeth Bleaching Compositions and Devices
US9427384B2 (en) 2006-01-23 2016-08-30 Dental Alliance Holdings, Llc System for caries management by risk assessment
US9849310B2 (en) 2008-06-24 2017-12-26 Dental Alliance Holdings, Llc Dental appliance, oral care product and method of preventing dental disease
US9968526B1 (en) 2005-01-24 2018-05-15 Dental Alliance Holdings, Lll System for caries management by risk assessment
US10143633B2 (en) 2006-10-16 2018-12-04 Dental Alliance Holdings, Llc Treating cariogenic diseased oral biofilm with elevated pH
WO2021119043A3 (en) * 2019-12-09 2021-08-05 Corning Incorporated Bioactive glass as nucleic acid carriers with ph switch control-releasing
US20240108570A1 (en) * 2012-06-22 2024-04-04 Unisa Ventures Pty Ltd Method and composition for delivering a compound through a biological barrier

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191261B (en) * 1997-09-18 2003-10-18 Univ Maryland
US6383519B1 (en) * 1999-01-26 2002-05-07 Vita Special Purpose Corporation Inorganic shaped bodies and methods for their production and use
DE19910559A1 (en) * 1999-03-10 2000-09-14 Espe Dental Ag Subgingival powder blasting
US6458162B1 (en) 1999-08-13 2002-10-01 Vita Special Purpose Corporation Composite shaped bodies and methods for their production and use
US20040009228A1 (en) * 1999-11-30 2004-01-15 Pertti Tormala Bioabsorbable drug delivery system for local treatment and prevention of infections
DE10014416B4 (en) 2000-03-24 2009-02-19 3M Espe Ag Use of fine-grained powders or powder mixtures for producing an agent for supragingival powder blasting
EP1392611B1 (en) * 2001-03-30 2005-05-18 King's College London Use of bioactive glass for cutting bioactive glasses
US7204875B2 (en) * 2001-10-24 2007-04-17 Pentron Clinical Technologies, Llc Dental filling material
US7211136B2 (en) * 2001-10-24 2007-05-01 Pentron Clinical Technologies, Llc Dental filling material
US7750063B2 (en) 2001-10-24 2010-07-06 Pentron Clinical Technologies, Llc Dental filling material
US7303817B2 (en) * 2001-10-24 2007-12-04 Weitao Jia Dental filling material
US7204874B2 (en) * 2001-10-24 2007-04-17 Pentron Clinical Technologies, Llc Root canal filling material
BRPI0300644B8 (en) * 2003-02-20 2022-04-26 Fundacao Univ Federal De Sao Carlos Process of preparing particulate, bioactive and resorbable biosilicates, compositions for preparing said biosilicates and bioactive and resorbable particulate biosilicates.
US20070264291A1 (en) * 2003-12-19 2007-11-15 Greenspan David C Compositions and Methods for Preventing or Reducing Plaque and/or Gingivitis Using a Bioactive Glass Containing Dentefrice
US9220595B2 (en) 2004-06-23 2015-12-29 Orthovita, Inc. Shapeable bone graft substitute and instruments for delivery thereof
DE102005001078A1 (en) * 2005-01-08 2006-07-20 Schott Ag Glass powder, in particular biologically active glass powder and process for the production of glass powder, in particular biologically active glass powder
DE102005049972A1 (en) * 2005-10-17 2007-04-19 Henkel Kgaa Tingling oral and dental care and cleaning products
DE102005049973A1 (en) * 2005-10-17 2007-04-19 Henkel Kgaa Tingling oral and dental care and cleansers II
EP2040765A2 (en) 2006-06-29 2009-04-01 Orthovita, INC. Bioactive bone graft substitute
US20090035227A1 (en) * 2007-07-31 2009-02-05 Stephan Hausmanns Confectionery products comprising a tooth-friendly sweetener
GB0813494D0 (en) * 2008-07-23 2008-08-27 Osspray Ltd Method
US20100086497A1 (en) * 2008-10-08 2010-04-08 Biofilm Limited Tooth remineralisation
AR076179A1 (en) 2009-04-01 2011-05-26 Colgate Palmolive Co NON-WATERPROOF DIFFERENT COMPOSITION WITH BIOACCEPTABLE AND BIOACTIVE GLASS AND METHODS OF USE AND MANUFACTURING OF THE SAME
AR076178A1 (en) 2009-04-01 2011-05-26 Colgate Palmolive Co DOUBLE ACTION DENTIFRIC COMPOSITIONS TO PREVENT HYPERSENSITIVITY AND PROMOTE REMINERALIZATION
ATE539778T1 (en) 2009-04-23 2012-01-15 Vivoxid Oy BIOCOMPATIBLE COMPOSITE AND ITS USE
EP2448607A1 (en) * 2009-06-29 2012-05-09 BonAlive Biomaterials Oy A bioactive glass for use in conditions relating to bone infections
EP2322134B1 (en) 2009-11-12 2012-09-12 BonAlive Biomaterials Oy Implantable paste and its use
US8778378B2 (en) 2009-12-21 2014-07-15 Orthovita, Inc. Bioactive antibacterial bone graft materials
US8715625B1 (en) 2010-05-10 2014-05-06 The Clorox Company Natural oral care compositions
RU2460076C1 (en) * 2011-03-30 2012-08-27 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" (ФБУН "Уфимский НИИ медицины труда и экологии человека") Early diagnostic technique for oral diseases in adolescents by microelement composition and lactic acid bacilli concentration in non-stimulated oral fluid
FI20115968A0 (en) 2011-10-03 2011-10-03 Oy Granula Ab Ltd ANHYDROUS SUSPENSIONS, ANTIMICROBIC GELS AND THEIR APPLICATIONS
PL2875832T3 (en) * 2014-03-17 2016-12-30 Implantable paste and its use
CN111093604B (en) 2017-08-18 2023-12-08 联合利华知识产权控股有限公司 Oral care composition
CN110997072B (en) 2017-08-18 2022-11-08 联合利华知识产权控股有限公司 Oral care compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50339A (en) * 1973-05-07 1975-01-06
US4189325A (en) * 1979-01-09 1980-02-19 The Board of Regents, State of Florida, University of Florida Glass-ceramic dental restorations
US4851046A (en) * 1985-06-19 1989-07-25 University Of Florida Periodontal osseous defect repair
US4725234A (en) * 1985-08-15 1988-02-16 Ethridge Edwin C Alveolar bone grafting process with controlled surface active ceramics
JPS6267008A (en) * 1985-09-20 1987-03-26 G C Dental Ind Corp Fluoroaluminosilicate glass powder for dental glass ionomer cement
JPS6272540A (en) * 1985-09-26 1987-04-03 Nippon Electric Glass Co Ltd Alkaliless crystallized glass for organism and its production
US4839215A (en) * 1986-06-09 1989-06-13 Ceramed Corporation Biocompatible particles and cloth-like article made therefrom
US4737411A (en) * 1986-11-25 1988-04-12 University Of Dayton Controlled pore size ceramics particularly for orthopaedic and dental applications
JPH02149447A (en) * 1988-12-01 1990-06-08 Nippon Electric Glass Co Ltd Dental crystallized glass
US5074916A (en) * 1990-05-18 1991-12-24 Geltech, Inc. Alkali-free bioactive sol-gel compositions
DE4314817A1 (en) * 1993-04-30 1994-11-03 Ivoclar Ag Opalescent glass
JP2547953B2 (en) * 1994-02-07 1996-10-30 克成 西原 Artificial tooth root
JPH0848539A (en) * 1994-06-02 1996-02-20 Nippon Sheet Glass Co Ltd Antibacterial glass composition
JP3021287B2 (en) * 1994-07-01 2000-03-15 石塚硝子株式会社 Antibacterial agent for sandbox
FI104881B (en) 1994-10-06 2000-04-28 Bioxid Oy Process for preparing new compositions containing silicon-containing glass
FI101129B (en) * 1995-01-13 1998-04-30 Vivoxid Oy New bioactive glasses and their use
US5728753A (en) * 1995-11-09 1998-03-17 University Of London Bioactive composite material for repair of hard and soft tissues
US5681872A (en) * 1995-12-07 1997-10-28 Orthovita, Inc. Bioactive load bearing bone graft compositions
AU723659B2 (en) * 1996-01-29 2000-08-31 Novamin Technology, Inc. Bioactive glass compositions and methods of treatment using bioactive glass
HUP9901760A3 (en) 1996-01-29 1999-11-29 Usbiomaterials Corp Alachua Bioactive glass compositions and methods of treatment using bioactive glass
US5735942A (en) 1996-02-07 1998-04-07 Usbiomaterials Corporation Compositions containing bioactive glass and their use in treating tooth hypersensitivity
US6051247A (en) * 1996-05-30 2000-04-18 University Of Florida Research Foundation, Inc. Moldable bioactive compositions
US5977204A (en) * 1997-04-11 1999-11-02 Osteobiologics, Inc. Biodegradable implant material comprising bioactive ceramic
IN191261B (en) * 1997-09-18 2003-10-18 Univ Maryland
FR2770146A1 (en) 1997-10-29 1999-04-30 Salomon Sa Single axis roller skate

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551508B2 (en) 1999-12-07 2013-10-08 Schott Ag Cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
US20070275021A1 (en) * 1999-12-07 2007-11-29 Schott Ag New cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same
US20040151745A1 (en) * 2001-03-27 2004-08-05 Jose Zimmer Tissue abrasives
US7597900B2 (en) 2001-03-27 2009-10-06 Schott Ag Tissue abrasives
US20060142413A1 (en) * 2003-02-25 2006-06-29 Jose Zimmer Antimicrobial active borosilicate glass
EP1675554A4 (en) * 2003-09-29 2009-08-19 Schott Ag TISSUE ABRASIVES
JP2007507426A (en) * 2003-09-29 2007-03-29 ショット アクチエンゲゼルシャフト Tissue abrasive
US20070122356A1 (en) * 2004-05-29 2007-05-31 Schott Ag Glass compositions as an antimicrobial additive for dental materials
DE102004026432A1 (en) * 2004-05-29 2005-12-22 Schott Ag Glass compositions as antimicrobial additive for dental materials and their use
US9968526B1 (en) 2005-01-24 2018-05-15 Dental Alliance Holdings, Lll System for caries management by risk assessment
US9427384B2 (en) 2006-01-23 2016-08-30 Dental Alliance Holdings, Llc System for caries management by risk assessment
US20070258916A1 (en) * 2006-04-14 2007-11-08 Oregon Health & Science University Oral compositions for treating tooth hypersensitivity
US10143633B2 (en) 2006-10-16 2018-12-04 Dental Alliance Holdings, Llc Treating cariogenic diseased oral biofilm with elevated pH
US20090317339A1 (en) * 2008-06-23 2009-12-24 Deepak Sharma Teeth Bleaching Compositions and Devices
US9849310B2 (en) 2008-06-24 2017-12-26 Dental Alliance Holdings, Llc Dental appliance, oral care product and method of preventing dental disease
US20240108570A1 (en) * 2012-06-22 2024-04-04 Unisa Ventures Pty Ltd Method and composition for delivering a compound through a biological barrier
WO2021119043A3 (en) * 2019-12-09 2021-08-05 Corning Incorporated Bioactive glass as nucleic acid carriers with ph switch control-releasing
CN114829313A (en) * 2019-12-09 2022-07-29 康宁股份有限公司 Bioactive glass as nucleic acid carrier with pH-switched controlled release

Also Published As

Publication number Publication date
US6342207B1 (en) 2002-01-29
CA2272963A1 (en) 2000-09-02
CA2272963C (en) 2009-04-21
US6190643B1 (en) 2001-02-20

Similar Documents

Publication Publication Date Title
US6342207B1 (en) Method for reducing the viability of detrimental oral microorganisms in an individual, and for prevention and/or treatment of diseases caused by such microorganisms; and whitening and/or cleaning of an individual&#39;s teeth
Stoor et al. Antibacterial effects of a bioactive glass paste on oral microorganisms
Allan et al. Antibacterial activity of particulate Bioglass® against supra-and subgingival bacteria
Zehnder et al. Preliminary evaluation of bioactive glass S53P4 as an endodontic medication in vitro
Ullsfoss et al. Effect of a combined chlorhexidine and NaF mouthrinse: an in vivo human caries model study
JP2007515427A (en) Compositions and methods for preventing or reducing plaque and / or gingivitis using a bioactive glass-containing dentifrice
Butrón Téllez Girón et al. Therapeutic use of silver nanoparticles in the prevention and arrest of dental caries
Nivedhitha et al. Effects of zinc oxide nanoparticles in combination with conventional glass ionomer cement: in vitro study
Decker et al. Effect of xylitol/chlorhexidine versus xylitol or chlorhexidine as single rinses on initial biofilm formation of cariogenic streptococci.
Satyanegara et al. An invitro study of caries arresting effect of propolis fluoride and silver diamine fluoride on dentine carious lesions
Ezzeldin et al. Comparative evaluation of the antibacterial activity of Glass ionomer restoration incorporated with different metal oxides Nanoparticles on oral Streptococcus mutans
Rajadorai et al. Antibacterial, remineralizing zinc oxide-doped phosphate-based glasses
US20100266990A1 (en) Dental antimicrobial formulations and methods of using the same
Ge et al. Preventing proximal enamel caries in neighboring tooth with glass ionomer cement restoration and silver diamine fluoride pretreatment
Butrón-Téllez Girón et al. Antibacterial effect, antiadherence, and antiacidogenicity properties of a dental varnish containing silver nanoparticles: an in vitro study
Elbanna et al. Antibacterial behavior of calcium fluoride-modified tricalcium silicate cement against different oral bacterial strains
Liu et al. Antibacterial and Antibiofilm Activity of Commercial Mouthwashes against Streptococcus mutans: An In Vitro Study
Pierry Effect of Herbal Extracts on Oral Microorganisms
Crovace et al. Bioactive Glass and Glass-Ceramics for Managing Microbial Infections
Talaat Effect of probiotic chewable tablets on oral health and white spot lesions in pre-school children: a randomized clinical trial
鄧帆 Development of novel zinc ion-releasing glasses
Srikumar et al. Evaluation of antibacterial effectiveness of various chemical and herbal root canal irrigants against Enterococcus faecalis: an in vitro study
Soekanto et al. Efficacy of propolis fluoride in inhibiting the formation of Streptoccocus mutans, Streptococcus gordonii, and Streptococcus sanguinis biofilm
Kandil et al. Remineralizing Potential and Antibacterial Effect of Different Mouthwashes on Demineralized Enamel in Acidic challenges: an Invitro Study
Darwita et al. A comparative evaluation of the number of streptococcus mutans colonies in the enamel surface of teeth after the application of CPP-ACP containing propolis and CPP-ACP without propolis

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION